金融界2025年8月12日消息，中欧医疗创新股票A(006228) 最新净值1.6867元，下跌1.36%。该基金近1个 月收益率14.93%，同类排名75|1022；近6个月收益率61.44%，同类排名25|986；今年来收益率62.21%， 同类排名24|976。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活 ...

Group 1 - The core viewpoint of the article is that the Chinese innovative pharmaceutical sector is experiencing a resurgence, with the reopening of the IPO window on the Sci-Tech Innovation Board (STAR Market) leading to increased activity and optimism among investors [1][3][11] - The STAR Market's fifth set of listing standards was reactivated in June 2023, allowing unprofitable biotech companies to pursue IPOs, which had been stalled for two years [3][4] - Several companies, including He Yuan Bio and Bei Xin Life, have successfully passed IPO approvals under the new standards, indicating a growing pipeline of innovative drug companies ready to enter the market [4][5] Group 2 - The Hong Kong stock market has also seen significant gains in the healthcare sector, with the medical and healthcare index rising over 45% in the first half of 2025, outperforming other sectors [8][9] - Notable companies like Song Li Pharmaceutical and Deqi Pharmaceutical have achieved remarkable stock price increases, with some stocks rising tenfold, reflecting a strong recovery in the market [8][9] - The successful IPO of Ying En Bio in April 2023, which saw a first-day surge of over 116%, exemplifies the renewed investor interest and the potential for high returns in the biotech sector [10] Group 3 - The article highlights a shift in investor sentiment towards the pharmaceutical sector, with many previously cautious investors now recognizing the long-term potential of innovative drug companies [11][12] - There has been a notable increase in business development (BD) transactions involving Chinese pharmaceutical assets, indicating growing international recognition of Chinese innovation in drug development [12] - The article suggests that the next 5-10 years could be a favorable period for investment in Chinese innovative pharmaceuticals, as the industry is expected to continue its recovery and growth [12][13]

Core Viewpoint - The article highlights the resurgence of the Chinese biopharmaceutical industry, particularly focusing on the recent openings for IPOs on the STAR Market, signaling a potential recovery and growth phase for innovative drug companies in China [3][5][12]. Group 1: IPO Developments - The STAR Market has reopened its doors for innovative drug companies, with the first successful IPOs occurring after a long hiatus, including companies like He Yuan Bio and Bei Xin Life [5][6]. - Biotech company Bibet has received approval for its IPO after three years of waiting, marking a significant milestone for the company and the industry [3][6]. - The approval of the fifth set of listing standards for unprofitable companies on the STAR Market has revitalized the IPO landscape for the biopharmaceutical sector [5][12]. Group 2: Market Performance - The Hong Kong stock market has seen a remarkable performance in the healthcare sector, with the healthcare index rising over 45% in the first half of 2025, outperforming other industries [9][10]. - Notable stocks like Gilead Sciences and others have experienced significant price increases, with some companies achieving tenfold returns, indicating a strong recovery in investor sentiment [9][10]. - The successful IPO of companies like Ying En Bio, which saw a first-day surge of over 116%, reflects the growing investor interest and confidence in the biopharmaceutical sector [11]. Group 3: Investment Trends - There is a notable shift in investment focus back to the biopharmaceutical sector, with many investors previously hesitant now recognizing the potential for growth and returns [12]. - The article mentions that international investors are increasingly aware of the value of Chinese innovative drug companies, with many regretting missed opportunities in the Hong Kong market [10][12]. - The trend of mergers and acquisitions in the biopharmaceutical space is on the rise, with significant deals indicating a growing recognition of the quality of Chinese assets [12][13].

Core Viewpoint - The Hong Kong stock market's innovative drug sector has seen a significant rebound in performance this year, driven by favorable policies, accelerated R&D, and a surge in overseas expansion. The Hang Seng Innovative Drug Index (HSIDI.HI) has gained over 100% year-to-date, attracting considerable market attention. In light of this positive trend, the index's compilation rules have undergone important revisions [1][2]. Summary by Relevant Sections Index Adjustments - On August 1, 2025, the Hang Seng Index Company announced key revisions to the Hang Seng Innovative Drug Index, effective from August 11, 2025. The main changes include the removal of companies in the CXO sector, which encompasses Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), and Contract Development and Manufacturing Organizations (CDMO) [1][2]. Focus on Core Enterprises - The index has removed seven companies with relatively low "innovative drug content," resulting in a renewed focus on core innovative drug enterprises. These companies typically possess strong R&D capabilities and core patent technologies, enhancing the index's ability to capture the industry's driving forces [3][5]. Top Constituents and Their Weightings - The top ten constituents of the revised index and their respective weights are as follows: - 9926.HK: 10.31% - 6160.HK: 9.80% - 1801.HK: 9.52% - 1177.HK: 9.47% - 6990.HK: 9.18% - 1093.HK: 6.98% - 1952.HK: 6.22% - 9688.HK: 6.12% - 1530.HK: 5.90% - 2157.HK: 2.94% [4]. Enhanced Liquidity and Trading Efficiency - The index's selection criteria have been modified to include only companies eligible for trading under the Southbound Stock Connect, thereby enhancing liquidity and trading convenience. This change is expected to attract more mainland capital, further improving the index's trading dynamics [7]. Investment Opportunities - The Huatai-PineBridge Fund's Hang Seng Innovative Drug ETF (520500) is the first ETF tracking the Hang Seng Innovative Drug Index. As of August 8, 2025, the ETF has seen a significant increase in both shares and scale, with year-to-date growth rates of 389.34% and 854.55%, respectively. The ETF has also demonstrated strong liquidity, with daily trading volumes exceeding 1 billion HKD for 15 consecutive trading days [8].

Core Viewpoint - The "2025 Guangzhou Medical and Health Industry Expo" will be held from August 22 to 24, 2025, showcasing cutting-edge technologies and facilitating deep exchanges among industry experts, scholars, and enterprises in the medical health sector [1] Group 1: Scale and Participation - The expo will cover an exhibition area of 30,000 square meters, featuring 3 exhibition halls and 18 exhibition zones, with an expected participation of over 400 exhibitors from various sectors including medical institutions, biopharmaceutical companies, and financial institutions [2] - The event will host nearly 20 high-level conferences, inviting leaders from the National Health Commission, hospital directors, and top experts to share the latest research and practical experiences [2] Group 2: Collaborative Efforts - The preparation for the expo has seen a rapid response, with over 500 invitations sent out, attracting participation from health commissions across various provinces, showcasing the industry's collaborative spirit [3] - Over 100 enterprises, including major pharmaceutical companies and innovative firms, will present their technologies and products, contributing to a diverse and synergistic medical industry ecosystem [3] Group 3: Government Support - The expo will invite leaders from various government levels to provide direct guidance and support to enterprises, focusing on policy interpretation and project roadshows to facilitate financing [4] - The government aims to integrate resources from medical and research institutions to support enterprises in technology transfer and innovation [4] Group 4: Innovation and Development - The expo will focus on the entire chain of the biopharmaceutical and health industry, promoting high-quality development of innovative drugs and showcasing over 100 biopharmaceutical enterprises and research institutions [5] - Cutting-edge technologies such as gene editing, cell therapy, and 3D printing will be highlighted, representing the future direction of industry development [5] Group 5: New Collaboration Models - The expo will introduce a "four-level tour" model to enhance collaboration between hospitals and enterprises, supported by a government-led research hospital alliance [6] - This innovative model aims to improve cooperation efficiency and promote high-quality development in the medical health industry, providing a replicable example for national collaboration [7]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing renewed performance with active trading and significant capital inflow, particularly in the Hang Seng Innovative Drug ETF (520500), which has seen its scale grow over 916% year-to-date [1][2]. Group 1: Market Performance - The Hang Seng Innovative Drug ETF (520500) has recorded a net inflow of funds for four consecutive trading days, reaching a total of 633 million shares and a scale of 1.23 billion yuan as of August 11, 2025, both hitting new highs since its inception [1]. - The ETF has maintained a high trading volume, with over 1 billion yuan in daily trading for 15 consecutive days from July 22 to August 11, averaging 1.39 billion yuan per day [1]. Group 2: Industry Trends - Several innovative drugs have recently been included in the public notice period for breakthrough therapies, which may catalyze future commercialization and profitability in the sector [1]. - Foreign investment banks have released optimistic reports on the Hong Kong innovative drug sector as the mid-year reporting period approaches, indicating a sustained positive outlook [1]. - The innovative drug sector has seen rapid growth in product revenue and external licensing over the past three years, with significant business development transactions occurring this year [1]. Group 3: Index and ETF Details - The Hang Seng Innovative Drug Index, tracked by the ETF, has been revised to focus on core innovative pharmaceutical companies, enhancing its ability to capture the industry's driving forces [1]. - The index currently includes 29 constituent stocks, with the top five being Innovent Biologics, BeiGene, I-Mab, China National Pharmaceutical Group, and Kelun-Biotech, all of which possess strong R&D capabilities and core patent technologies [1]. - The ETF is managed by Huatai-PB Fund, which has over 18 years of experience in ETF operations, having developed several benchmark products [1].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

Group 1 - Xiaomi Group-W (01810), SMIC (00981), and Alibaba-W (09988) ranked the top three in net inflow of southbound funds, with net inflows of 1.716 billion, 0.497 billion, and 0.492 billion respectively [1] - The top three stocks with the highest net outflow of southbound funds were the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and China Mobile (00941), with net outflows of -4.725 billion, -1.560 billion, and -0.794 billion respectively [1] - In terms of net inflow ratio, Reshape Energy (02570), Haitian International (01882), and Guofu Hydrogen Energy (02582) led the market with ratios of 69.81%, 56.10%, and 54.91% respectively [1] Group 2 - The top ten stocks by net inflow included Xiaomi Group-W (01810) with 1.716 billion and a closing price of 51.850, down 3.98% [2] - The top ten stocks by net outflow included the Tracker Fund of Hong Kong (02800) with -4.725 billion and a closing price of 25.560, up 0.55% [2] - The highest net inflow ratio was recorded by Reshape Energy (02570) at 69.81% with a closing price of 167.000, up 1.33% [3]

Summary of Key Points Core Viewpoint - On August 11, the Hang Seng Index rose by 0.19%, with southbound funds totaling a transaction amount of HKD 115.814 billion, resulting in a net inflow of HKD 0.38 million [1]. Group 1: Southbound Fund Transactions - The total transaction amount for southbound funds was HKD 115.814 billion, with buy transactions at HKD 57.926 billion and sell transactions at HKD 57.888 billion, leading to a net buy of HKD 0.38 million [1]. - The southbound trading through the Shenzhen Stock Connect amounted to HKD 46.075 billion, with net buying of HKD 2.19 million, while the Shanghai Stock Connect saw a net sell of HKD 1.80 million [1]. Group 2: Active Stocks - The most actively traded stock by southbound funds was SMIC, with a total transaction amount of HKD 54.92 billion, followed by Tencent Holdings and Xiaomi Group-W with transaction amounts of HKD 34.86 billion and HKD 32.18 billion, respectively [1]. - Xiaomi Group-W had the highest net buy amount of HKD 5.62 million, despite a closing price drop of 0.88%, while XPeng Motors had the highest net sell amount of HKD 6.65 million, with a closing price increase of 5.36% [1]. Group 3: Continuous Net Buying - Two stocks, 康方生物 (Kangfang Biotech) and 小米集团-W (Xiaomi Group-W), experienced continuous net buying for more than three days, with net buying amounts of HKD 27.57 million and HKD 11.82 million, respectively [2].

8月11日上榜的成交活跃股中，康方生物通过港股通渠道成交金额为11.00亿港元，净买入金额为3.06亿港元，不仅如此，该股已连续5日出现成交 净买入，累计净买入金额为11.82亿港元，其间股价上涨5.72%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （原标题：康方生物获南向资金连续5天净买入） 康方生物获南向资金连续5天净买入，累计净买入金额为11.82亿港元，股价累计上涨5.72%。 证券时报•数据宝统计显示，8月11日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交294.32亿港元，净卖出金额为10.21亿港元。 ...